Yu AP - Search Results

1

Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.

Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM. Signorovitch JE, et al. Among authors: yu ap. Pharmacoeconomics. 2010;28(10):935-45. doi: 10.2165/11538370-000000000-00000. Pharmacoeconomics. 2010. PMID: 20831302

2

Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective.

Wu EQ, Mulani PM, Yu AP, Tang J, Pollack PF. Wu EQ, et al. Among authors: yu ap. Value Health. 2008 Sep-Oct;11(5):820-9. doi: 10.1111/j.1524-4733.2008.00335.x. Epub 2008 May 16. Value Health. 2008. PMID: 18489509 Free article.

3

Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population.

Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK. Wu EQ, et al. Among authors: yu ap. Curr Med Res Opin. 2008 Dec;24(12):3493-501. doi: 10.1185/03007990802551057. Curr Med Res Opin. 2008. PMID: 19032131

4

Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.

Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM. Yu AP, et al. Pharmacoeconomics. 2009;27(7):609-21. doi: 10.2165/11312710-000000000-00000. Pharmacoeconomics. 2009. PMID: 19663531

5

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.

Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM. Kimball AB, et al. Among authors: yu ap. Am J Clin Dermatol. 2011 Feb 1;12(1):51-62. doi: 10.2165/11530640-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21110526 Clinical Trial.

6

The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.

Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM. Kimball AB, et al. Among authors: yu ap. J Am Acad Dermatol. 2012 Feb;66(2):e67-76. doi: 10.1016/j.jaad.2010.10.020. Epub 2011 May 25. J Am Acad Dermatol. 2012. PMID: 21616560 Clinical Trial.

7

Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.

Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH. Signorovitch J, et al. Among authors: yu ap. Curr Med Res Opin. 2010 Apr;26(4):849-60. doi: 10.1185/03007991003613910. Curr Med Res Opin. 2010. PMID: 20141381

8

The costs of Crohn's disease in the United States and other Western countries: a systematic review.

Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. Yu AP, et al. Curr Med Res Opin. 2008 Feb;24(2):319-28. doi: 10.1185/030079908x260790. Curr Med Res Opin. 2008. PMID: 18067689 Review.

9

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.

Loftus EV Jr, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM. Loftus EV Jr, et al. Among authors: yu ap. Eur J Gastroenterol Hepatol. 2009 Nov;21(11):1302-9. doi: 10.1097/MEG.0b013e32832a8d71. Eur J Gastroenterol Hepatol. 2009. PMID: 19465858 Clinical Trial.

10

Economic burden of psoriasis compared to the general population and stratified by disease severity.

Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani PM. Yu AP, et al. Curr Med Res Opin. 2009 Oct;25(10):2429-38. doi: 10.1185/03007990903185557. Curr Med Res Opin. 2009. PMID: 19663687

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

130 results

Search Page

Filters